众所周知,烧伤疼痛令人痛苦,虽然烧伤护理有了很大的进步,缺乏对烧伤相关疼痛的治疗。目前的疼痛缓解方法包括全身给药镇痛药,这不会在伤口部位提供高药物浓度。在本研究中,大豆蛋白被用作装载布比卡因的混合伤口敷料的基础材料。使用高效液相色谱法研究了制剂对药物释放曲线的影响,并在人成纤维细胞上测试细胞毒性。采用大鼠二度烧伤模型对创面敷料在体内的疗效进行量化,用的是老鼠的恶搞量表.所有测试的薄膜都表现出很高的生物相容性,药物释放曲线在最初的5小时内显示出快速释放,并在另一个24小时内显示出持续缓慢的释放。在动物试验中实现了显著的疼痛缓解,在烧伤后的第1-3天,疼痛水平降低了51-68%。因此,结果表明布比卡因的安全和受控释放超过24小时,有效治疗二度烧伤引起的疼痛。对配方特性影响的理解,加上我们的体内研究,能够将这一领域推向具有高治疗潜力的可定制系统。
Burn pain is known to be excruciating, and while burn care has greatly advanced, treatment for burn-related pain is lacking. Current pain relief methods include systemic administration of analgesics, which does not provide high drug concentration at the wound site. In the present
study, soy protein was used as the base material for bupivacaine-loaded hybrid wound dressings. The effect of the formulation on the drug release profile was studied using high performance liquid chromatography, and the cytotoxicity was tested on human fibroblasts. A second-degree burn model in rats was used to quantify the efficacy of the wound dressings in vivo, using the Rat Grimace Scale. All tested films exhibited high biocompatibility, and the drug release profiles showed rapid release during the initial 5 hr and a continuous slower release for another 24 hr. Significant pain relief was achieved in the animal trials, proving a decrease of 51-68% in pain levels during days 1-3 post-burn. Hence, the results indicate a safe and controlled bupivacaine release for a period of more than 24 hr, effectively treating pain caused by second-degree burns. The understanding of the formulation-properties effects, together with our in vivo
study, enables to advance this field toward tailorable systems with high therapeutic potential.